LYN-005 matched daily risperidone in exposure while maintaining stability and offering a convenient long-acting option for ...

Risperidone alters key brain regions in schizophrenia, with future imaging tools offering insights into its long-term effects ...

WEDNESDAY, June 18, 2025 (HealthDay News) -- For patients with schizophrenia, weekly LYN-005 provides sustained release of risperidone at therapeutic concentrations, according to a study published ...

A Phase 3 clinical trial of a new once-weekly risperidone pill for schizophrenia shows it delivers comparable therapeutic effects to daily treatment, offering improved convenience and potential ...

Once-weekly risperidone (LYN-005) offers stable drug levels and reduces side effects, providing a promising new approach to treating schizophrenia.

Once-Weekly Oral Risperidone Shows Promise in Schizophrenia Treatment Once-weekly risperidone can maintain stable drug levels and reduce side effects in schizophrenia treatment.

For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be difficult to take their medicine every day.

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits.

A Randomized Double Blind Placebo Controlled Clinical Trial of N-Acetylcysteine Added to Risperidone for Treating Autistic Disorders ...

About UZEDY UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults.

Uzedy is an injection that contains the antipsychotic medicine risperidone. Uzedy helps control psychotic symptoms of schizophrenia, such as hallucinations and delusions.

A once-weekly version of oral risperidone (LYN-005) was comparable to daily dosing with immediate-release risperidone (Risperdal) for schizophrenia and schizoaffective disorder in the phase III ...